 The European Medicines Agency has granted Priority Medicines designation to Mustang Bio Incs NASDAQ: MBIO MB-107 for X-linked severe combined immunodeficiency X-SCID in newly diagnosed infants, also known as bubble boy disease. The Company is preparing to initiate a pivotal, multicenter Phase 2 clinical trial of MB-107 in newly diagnosed patients with X-SCID at the end of Q3. 